- In January 2022, QIAGEN announced its new Biotech Grants program winners, an initiative driven by the company's commitment to building strong partnerships with biotechnology and pharma businesses and helping them succeed in the market. This has helped the company in revenue growth
- In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT)
- In July 2024, Mursla Bio announced the launch of its novel extracellular vesicle (EV)-based diagnostic platform aimed at enhancing early detection of diseases such as cancer through liquid biopsy. The new platform enables ultra-sensitive and high-specificity analysis of biomarkers using EVs from blood samples, marking a significant step forward in non-invasive diagnostics. This innovation is expected to strengthen Mursla Bio’s position in the precision medicine market and drive revenue growth
